Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
19.49%
Operating Margin
14.67%
Net Margin
-4.18%
Efficiency Metrics
Revenue per Expense Ratio
1.17
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
58.17%
Income Tax Rate
0.00%
EPS
-0.2600000000
Balance Sheet Analysis
Current Ratio
1.48
Cash Ratio
0.91
Working Capital
$273.73M
Debt to Equity
2.51
Debt to Assets
57.79%
Equity Ratio
23.02%
Cash Flow Analysis
Operating Cash Flow Ratio
41.84%
Free Cash Flow Ratio
23.30%
CapEx to Revenue
18.54%
Dividends Paid
$129.90M
Stock Buybacks
$111.64M
Total Shareholder Returns
$241.53M
Cash Position Change
94.57%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
2.70%
Net Income
20.39%
EPS
16.13%
Operating Income
-39.34%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
8.44%
Operating Cash Flow
-14.07%
Free Cash Flow
-8.10%
Balance Sheet Health
Assets
-1.06%
Debt
6.75%
Book Value per Share
-6.80%
Inventory
150.64%
Shareholder Returns
Dividends per Share
-31.60%
Shares Outstanding
-3.50%
Long Term Trends
3Y Revenue/Share
18.37%
5Y Revenue/Share
15.99%
3Y Dividend/Share
-31.58%
5Y Dividend/Share
-23.38%